Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 45574 results
Heron discloses new IV formulation of NK-1 receptor antagonist to prevent CINV
Heron Therapeutics, a biotechnology company, has disclosed a development program for a P/neurokinin-1 (NK1) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV).
News
Micreos launches first bacteria-killing enzyme for human use asgainst MRSA
Micreos, a Dutch biotech, has developed Staphefekt, a bacteria-killing enzyme, or endolysin, specific to Staphylococcus aureus, which is equally effective in killing methicillin-resistant Staphylococcus aureus (MRSA) as methicillin-susceptible Staphylococcus aureus (MSSA).
News
Provectus submits PV-10 phase III melanoma protocol to FDA
Provectus Biopharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has submitted its phase III protocol for evaluation of PV-10 for treatment of locally advanced cutaneous melanoma to the FDA.
News
ViaCyte gets US patent claiming alternative methods to manufacture pancreatic progenitor cells in Vitro
ViaCyte, a privately-held regenerative medicine company developing a stem cell-derived islet replacement therapy for the treatment of diabetes, has been granted US patent 8,859,286, which describes methods for manufacture of human pancreatic progenitor cells from definitive endoderm cells, by the US Patent and Trademark Office.
News
PDL BioPharma acquires portion of Michigan University's royalty interest in genzyme's cerdelga for $65.6m
PDL BioPharma announced that it has acquired a portion of the University of Michigan's ("U-M") worldwide royalty interest in Cerdelga (eliglustat) for $65.6 million.
News
Auspex's SD-809 gets FDA orphan drug status to treat Huntington's disease
By PBR Staff Writer
US-based Auspex Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational compound SD-809 to treat Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behaviour and movements.
News
Perrigo agrees to buy OTC firm Omega Pharma for EUR3.6bn
By PBR Staff Writer
Ireland-based Perrigo Company has signed an agreement to acquire Belgian over-the-counter (OTC) healthcare firm Omega Pharma, for about €3.6bn.
News
AstraZeneca divests Myalept for $325m to Aegerion
By PBR Staff Writer
AstraZeneca has agreed to sell its Myalept (metreleptin for injection) drug to Aegerion Pharmaceuticals for an upfront payment of $325m.
News
Merrimack gets FDA orphan drug designation for pancreatic cancer drug candidate MM-141
By PBR Staff Writer
Merrimack Pharmaceuticals has secured orphan drug designation from the US Food and Drug Administration (FDA) for its investigational drug candidate MM-141 to treat pancreatic cancer.
News
MPI, Alion to develop drug response predictors for ion channel inhibitors in oncology
By PBR Staff Writer
Medical Prognosis Institute (MPI) and Alion Pharmaceuticals have entered into a partnership to develop a specific Drug Response Predictor (DRP) to identify cancer patients likely to respond to an undisclosed ion channel inhibitor to treat certain cancers.
News
Celsion secures VHP approval to start Phase III OPTIMA liver cancer trial
Celsion has secured approval via Europe's centralized Voluntary Harmonization Procedure (VHP) to conduct the Phase III OPTIMA trial of ThermoDox in primary liver cancer, also known as hepatocellular carcinoma (HCC), in Europe.
News
MMRF leads new initiative to accelerate development of targeted therapies for multiple myeloma
The Multiple Myeloma Research Foundation (MMRF) announced an initiative designed to accelerate the evaluation of new investigational therapies for multiple myeloma (MM).
News
Invetech, Argos ink deal to support global production of fully personalized immunotherapies
Invetech, a global leader in instrument development, custom automation and contract manufacturing, and Argos Therapeutics, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases, have entered into an agreement under which Invetech will develop and supply manufacturing systems to support production needs for fully personalized immunotherapies based on Argos' Arcelis technology platform.
News
The Medicines Company enrolls first patient in Phase III studies of CARBAVANCE to treat serious bacterial infections
The Medicines Company announced enrollment of the first patient in its Phase 3 clinical trial program for CARBAVANCE (meropenem/RPX7009), an investigational intravenous antibiotic under development for the treatment of serious bacterial infections due to gram-negative bacteria, particularly KPC (Klebsiella pneumoniae carbapenemase)-producing carbapenem-resistant Enterobacteriaceae (CRE).
News
BioLineRx reports final results of Phase I/II trial for new celiac treatment
BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, has announced successful final results from its Phase I/II study for BL-7010, a novel co-polymer for the treatment of celiac disease.
News
136-150 of 45574 results